What it tries to do
PanicFade v4 is a contrarian mean-reversion strategy. It buys large caps hit by a negative sentiment shock (headline sentiment below −0.4) while already technically oversold — RSI14 under 35 and trading below the 20-day moving average — on the premise that negative-headline overreactions revert toward fundamentals. It sizes into the panic and exits on reversion (RSI14 back above 50, or price reclaiming the SMA20), with a hard stop on fresh lows it reads as a genuine fundamental break rather than noise. The logic is grounded in 2025 sentiment-asymmetry research (arXiv:2509.11970) rather than curve-fitting — a point in its favour.
Recent activity
The book was reset to $10,000 on 29 October and has traded since. The runs on 30 October, 2 and 3 November executed 3, 3 and 2 orders respectively with zero rejections — buys in GOOGL, CAT, BAC and NVDA. The activity shows the strategy's characteristic churn: a CAT lot opened at $622.54 on 30 October was sold at $613.49 on 2 November (a small loss), while a GOOGL lot round-tripped from $280.28 to $282.94 (a small gain), with both names re-bought the next day. As of the 3 November run the account sits at $9,884.31 — roughly 1.2% below the reset line. Early days, but it is underwater.
Backtest and validation
Over 1,233 trading days the backtest returned 37.93% (final equity $13,793), a 6.79% CAGR, Sharpe 0.96 and a contained 9.3% max drawdown, with a 62.9% win rate across 530 trades. Validation is the stronger story: four walk-forward folds, all positive (1.6%, 3.9%, 10.1%, 21.7%), with out-of-sample return of 21.7% and OOS Sharpe of 2.44 in the latest window. After 27 trials the deflated Sharpe (DSR) lands at 0.56 and the probabilistic Sharpe (PSR) at 0.985 — it passed the gate, and a reviewer signed off at risk 0.35.
Strengths and risks
The strengths are real: every fold positive, a published thesis, disciplined exits and sanity-banded stops. But the concerns are not empty. Turnover is enormous — 5,807% — so this is a high-churn book whose edge must survive real-world fees and slippage. The 6.79% CAGR is modest for that activity, and the first fold (the 2021–22 bear) returned just 1.6% alongside the deepest 9.3% drawdown: precisely the regime where "buy the panic" risks catching falling knives on continued negativity. A DSR of 0.56 after 27 trials is a pass, not a comfortable margin. And the Improver's own verdict is telling — three attempts failed to beat the development-window gate, so this is the best available version, not a refined one. A slightly red live start is consistent with a strategy that needs a genuine sentiment washout to shine; the coming weeks of real quotes will matter more than any backtest.